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Abstract 
The COVID-19 pandemic has markedly impacted on cultural, political, and economic structures all over the world. 
Several aspects of its pathogenesis and related clinical consequences have not yet been elucidated. Infection rates, 
as well morbidity and mortality differed within countries. It is intriguing for scientists to understand how patient 
genetics may influence the outcome of the condition, to clarify which aspects could be related the clinical variability 
of SARS-CoV-2 disease. We reviewed the studies exploring the role of human leukocyte antigens (HLA) genotypes on 
individual responses to SARS-CoV-2 infection and/or progression, discussing also the contribution of the immunologi-
cal patterns MHC-related. In March 2021, the main online databases were accessed. All the articles that investigated 
the possible association between the HLA genotypes and related polymorphisms with susceptibility, severity and 
progression of COVID-19 were considered. Although both genetic and environmental factors are certainly expected 
to influence the susceptibility to or protection of individuals, the HLA and related polymorphisms can influence sus-
ceptibility, progression and severity of SARS-CoV-2 infection. The crucial role played by HLA molecules in the immune 
response, especially through pathogen-derived peptide presentation, and the huge molecular variability of HLA 
alleles in the human populations could be responsible for the different rates of infection and the different patients 
following COVID-19 infection.
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Background
In December 2019 a cluster of pneumonia cases caused 
by an unknown etiological agent broke out in Wuhan 
[1]. A novel coronavirus was subsequently identi-
fied, sequenced and finally confirmed as the agent that 
caused the disease [2, 3]. In February 2020 the patho-
gen was named “Severe Acute Respiratory Syndrome 
Coronavirus-2” (SARS-CoV-2) by the International Clas-
sification Committee of Viruses [4]. At the same time, 
the associated disease was named “Coronavirus Disease 
2019” (COVID-19) by the World Health Organization 
(WHO). COVID-19 currently represents a global pan-
demic with over 140 million confirmed cases and nearly 
3 million deaths worldwide (updated to April 2021) [5]. 
One year after its appearance the infection has spread 
on all continents and the emergence of SARS-CoV-2 
has caused one of the major public health and economic 
crises [6]. Considering the current situation, it would 
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as well reliable predictors, to counter this pandemic. In 
this context, the role of the Human Leukocyte Antigens 
(HLA) complex appears particularly interesting, since its 
genetic variability is directly associated with individual 
variations in the immune response against pathogens and 
susceptibility to infectious diseases [7].
Coronavirus
Coronaviruses are a wide group of viruses of enveloped 
positive-sense single-stranded RNA [8, 9]. Various types 
have been described: alpha, beta, delta, and gamma, but 
only alpha and beta coronavirus are known to infect 
humans [10, 11]. SARS-CoV-2 is a Betacoronavirus that 
shows many similarities [12, 13], including genomic [14, 
15] and immune system response [16–20], to other cor-
onaviruses [21], especially SARS-CoV and MERS-CoV 
[22–25]. Given the genomic similarity of SARS-CoV-2 
to coronaviruses isolated in bats, the virus likely has a 
zoonotic origin, with bats themselves a natural reservoirs 
and other animals (e.g., snakes) as intermediate hosts 
[26, 27]. However, currently the predominant mode of 
transmission is between humans, through droplets emit-
ted with coughs and sneezes [28]. The virions structure is 
characterized by the nucleocapsid protein and the spike 
glycoprotein. The glycoprotein S determines the specific-
ity of the virus for the epithelial cells of the gastrointes-
tinal and respiratory tracts because it is able to interact 
with transmembrane serine protease 2 (TMPRSS2) and 
angiotensin converting enzyme 2 (ACE2) receptors [29, 
30]. ACE2 receptors are ubiquitous and widely expressed, 
in particularly on the cell surface of type II pneumocytes 
[31, 32]. The virus, therefore, shows high tropism for the 
lungs, causing fever, fatigue, cough, dyspnea, and pneu-
monia (CAP) [33]. Most patients present mild disease 
and develop an efficient immune reaction [34]. Some 
patients develop acute respiratory distress syndrome 
(ARDS), requiring intubation and mechanical ventila-
tion (MV) in and intensive cares. Patients, often, suffer 
multi-organ dysfunction with high risk of death [34]. 
Patients over 65, particularly males, with comorbidities 
or organ-associated pathologies are at a higher risk of 
developing a severe, critical or even fatal disease course 
[35]. Type I diabetes mellitus has been also associated 
with severe clinical syndrome of SARS-CoV-2 infec-
tion. Hypertension and cardiovascular disease, obesity 
and/or a pro-inflammatory, and pro-coagulative state 
are also associated to the risk of worse outcome [36]. A 
dysregulated immune response participates in the sud-
den deterioration of COVID-19 patients, causing damage 
to infected and uninfected tissues. As with SARS-CoV-1 
[37] and MERS-CoV [38, 39], children showed low sus-
ceptibility to the disease [40, 41]. Infection rates seem 
similar to those seen in adults [42], but only 5.9% of 
pediatric cases were severe or critical, possibly conse-
quent to the lower binding ability of the ACE2 receptor 
in children or generally higher levels of antiviral antibod-
ies [43].
HLA locus
The human leukocyte antigen (HLA) gene complex is a 
locus of genes present on chromosome 6 that encodes 
proteins known ad major histocompatibility complexes 
(MHC). They constitute a specific group of molecules 
expressed on the cell surface, crucial for the recogni-
tion of non-self-molecules by the acquired immune sys-
tem [44]. The essential function of MHCs is to bind and 
expose antigens derived from pathogens, to present them 
to the appropriate T lymphocytes, triggering the immune 
response. In particular, MHC molecules class I expose 
peptide antigens, present within the cytoplasm activating 
CD4 T-cell response [45], while MHC molecules class II 
expose peptide antigens present in the extracellular space 
activating CD8 T-cell response [46]. As HLA genes are 
a critical component of the antigen presentation path-
way, they play a vital role in determining susceptibility to 
infectious disease. The HLA alleles are variable and poly-
morphic, and individuals with different HLA genotypes 




The literature search of the present systematic review was 
conducted according this protocol:
• Patients: SARS-CoV-2 infection;
• Comparison: HLA alleles;
• Outcomes: susceptibility, severity and progression of 
COVID-19.
Literature search
In April 2021 the following databases were accessed: Pub-
med, Embase, Scopus, Web of Science, Google Scholar. 
The following keywords were used in combination: 
coronavirus, COVID-19, SARS-CoV-2, SARS-CoV-1, 
MERS, infection, susceptibility, severity, progression, 
HLA, MHC, haplotypes, genotypes, locus, genes, alleles, 
polymorphisms, frequency, antigens, epitope, peptide, 
binder, factors, outcome, affinity, T cells, B cells, NK 
cells, lymphocyte, antibodies, association, correlation, 
genetic, pathogenesis, disease, immunology, virus, sys-
tem, humoral, cellular, response, adaptive, interaction, 
epidemic, role, manifestation, clearance, risk, cytokines, 
dysregulation, affinity, clinic, injury, prognosis, diagnosis, 
therapy, variability, distribution, inflammatory, reaction, 
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mortality, morbidity. If title and abstract matched the 
topic, the full-text was accessed. The bibliographies of 
the full-text articles were also screened for inclusion. 
Disagreements were solved by a third author (**). All the 
articles that investigate possible association between the 
HLA genotypes and related polymorphisms with suscep-
tibility, severity, and progression of COVID-19 were con-
sidered. According to the authors language capabilities, 
articles in English, French, German, Italian, and Spanish 
were considered.
Results
Based on the experience gained during the previous 
severe acute respiratory syndrome (SARS) and middle 
east respiratory syndrome (MERS) epidemics, it is likely 
that both innate and adaptive host immunity play a role 
in viral clearance, disease severity and the different clini-
cal manifestations of the disease [49–52]. Studies on the 
SARS-CoV-1 virus identified HLA polymorphisms asso-
ciated with the disease risk in the Asian population [53–
58]. Also, in SARS-CoV-2 infection, different HLA alleles 
of the major histocompatibility complex may define indi-
vidual susceptibility to infection [59].
Immune system
Recent data suggest that appropriate innate and adaptive 
T cell-mediated humoral and cellular immune responses 
could help elimination of the SARS-CoV-2 virus, which 
in most cases coincides with clinical recovery [60]. On 
the other hand, an excessive cell-mediated and dysregu-
lated innate and adaptive immune response can lead to 
an aggressive inflammatory reaction with the release of 
large amounts of pro-inflammatory cytokines. This con-
dition, known as “cytokine storm”—resulting from the 
excessive production of cytokines by immune cells such 
as the innate dendritic cells, macrophages, natural killer 
(NK) cells, and the adaptive T and B cells—directly cor-
relates with lung injury, ARDS and MOF, and leads to an 
unfavorable prognosis [61, 62]. Immunogenetic variation 
in humans could be an important target for clinical diag-
nosis and therapeutic intervention [63]. Binding between 
peptide epitopes and HLA proteins significantly contrib-
utes to cellular immune response mechanisms in human 
beings [64].
Non‑European HLA alleles
Several studies described the pivotal role of peptides in 
the specificity, magnitude and quality of both humoral 
and cellular immune responses. In silico studies have 
greatly facilitated analysis of the binding affinity between 
all the viral peptides of SARS-CoV-2 and different HLA 
class I genotypes. The HLA-B*46:01 allele has a low bind-
ing affinity, suggesting that subjects with this allele may 
have a higher risk of developing the more severe forms 
of COVID-19 [65], as previously shown with SARS-
CoV [53]. On the other hand, the HLA-B*15:03 allele is 
reported to have the highest binding affinity for viral pep-
tides [65]. On the contrary, the association with HLA-
B*46:01 was not observed in the study by Yung et  al., 
possibly because the T cell-mediated response could 
be a variable process, involving various factors, and not 
limited to HLA–peptide interactions [66]. However, the 
HLA-B22 serotype is a potential risk marker for SARS-
CoV-2 infection [67]. In this regard, a recent study about 
the HLA binders reported that five B22 alleles (B*54:01, 
B*55:01, B*55:07, B*55:12 and B*56:01) were among the 
94 weakest HLA-B binders to SARS-CoV-2, further sug-
gesting B22 as a susceptibility marker [68]. The published 
data seem to suggest also a possible role of the HLA-B27 
serotype in modulating SARS-CoV-2 infection [67]. B27 
serotype mediates protection against HCV and HIV [69]. 
The same HLA markers may be also associated with sus-
ceptibility/resistance to all SARS-CoV-2, HIV, and HCV, 
may have a common general immune mechanism against 
viral infections. Indeed, all the three viruses are RNA 
viruses. In particular, SARS-CoV-2 and HCV are posi-
tive-sense RNA viruses, which share striking sequence 
and structural homology in their RNA polymerase and 
protease, central components for viral replication [70, 
71]. Liver diseases have also been reported in COVID-
19 patients, more prevalently in severe cases [72]. On 
the other hand, lymphopenia is the clinical hallmark of 
HIV infection, associated with increased COVID-19 
severity [73]. Altered immune homeostasis could play 
a role in the pathogenesis of coronavirus disease. High 
binding affinity between SARS-CoV-2 epitopes and the 
HLA-A*02:06, HLA-B*52:01, and HLA-C*12:02 alleles 
has been also reported. In particular, two epitopes dis-
played strong binding affinity for HLA-A*24:02, HLA-
A*02:01, and HLA-A*02:06 [74]. Unfortunately, these 
studies present mathematical predictions that need to be 
more statistically robust and better define the appropri-
ate immunogenetic characteristics. Equally interesting is 
the study that reported the distribution of HLA allele fre-
quencies in 82 Chinese individuals with COVID-19 and 
identified HLA-C*07:29 and HLA-B*15:27 and HLA-B 
as statistically significant [75]. However, in this study 
HLA-C*07:29 was found in one COVID-19 patient only, 
but in no individuals in the control group. Therefore, the 
significance of these findings should be interpreted with 
caution, and this result needs to be confirmed in stud-
ies with larger sample sizes. Another study of Chinese 
patients with COVID-19 reported that the HLA-A*11:01, 
HLA-B*51:01 and HLA-C*14:02 alleles were signifi-
cantly associated with severe disease or worse outcome 
[76]. In another in silico analysis, the association of HLA 
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gene polymorphisms with prevalence and mortality of 
COVID-19 was examined and a possible association 
between HLA-A*02:01 and an increased risk for infection 
were identified. This allele had a relatively lower ability to 
present SARS-CoV-2 antigens compared with other fre-
quent HLA class I molecules, HLA-A*11:01 and HLA-
A*24:02 [77]. The HLA-A*24:02 allele was also involved 
in a study on bronchoalveolar lavage fluid and blood sam-
ples of COVID-19 patients [78], while the HLA-A*11:01 
allele, together with the HLA-A*02:06 and HLA-B*54:01 
alleles, could protect against infection [79].
European HLA alleles
In Italy, a study investigated whether specific class I HLA 
alleles could explain the huge differences observed for 
the spread of SARS-CoV-2 infection between Northern 
and Southern Italy. They compared HLA allele preva-
lence retrieved through the Italian Bone-Marrow Donor 
Registry with the incidence of SARS-CoV-2 infections 
in the different geographical regions. They showed how 
HLA-A*25, B*08, B*44, B*15:01, B*51, C*01, and C*03 
was positively associated with the incidence of SARS-
CoV-2 infection, while HLA-B*14, B*18, and B*49 
showed an inverse association. After applying a multiple 
regression model to eliminate confounding factors, only 
the HLA-C*01 and HLA-B*44 alleles, which are pre-
sent with a higher frequency in the northern regions of 
Italy, remained positively associated with COVID-19. In 
addition, this was confirmed by a sub-analysis between 
different provinces of the same region [80]. This epidemi-
ological analysis has made it possible to identify specific 
class I HLA alleles that are potentially unable to present a 
sufficient amount of virus-derived epitope peptides and, 
consequently, to trigger an adequate immune response 
to counteract SARS-CoV-2 infection. In this context, 
two individuals carrying the same antigen but differ-
ent HLA profile may give rise to a completely different 
T cell-mediated immune response, since they may have 
completely different amounts of HLA-specific antigen-
derived epitopes. This hypothesis has been confirmed in 
several studies concerning a number of different viruses 
as well as tumor antigens and autoimmune models [81–
87]. It can be assumed that, in these patients, the virus 
may freely spread from the oropharyngeal mucosae, 
starting a more efficient replication. Consistently, both 
HLA-B*44 and C*01 alleles, identified as possibly per-
missive to SARS-CoV-2 infection in Italy, have also 
been associated to known inflammatory autoimmune 
diseases [88–92], a fact that highlights their ability to 
trigger non-proficient and often inappropriate immuno-
logical reactions. Interestingly, the inheritance of HLA-
B*44 underlies susceptibility to recurrent sinopulmonary 
infection [93]. A further consideration stems from the 
knowledge that the HLA-C*01 allele, which was the 
most permissive to SARS-CoV-2 infection in that study, 
also represents the specific ligand of killer cell immuno-
globulin like receptors (KIRs), KIR2DL2 and KIR2DL3 
[94–96]. These receptors are able to inhibit the activ-
ity of natural killer cells, which represent the first line of 
host defense to the infection before the occurrence of a 
more specific T cell response [97]. A recent report found 
that peptides bound to HLA-C*05:01 are recognized by 
one of the activating KIR (KIR2DS4) [98] and this allele 
was significantly associated with the risk of death from 
COVID-19 [99]. Again, in Italy, another study, performed 
in Sardinia, evaluated statistically significant associa-
tion between local haplotypes and COVID-19. Almost a 
sanctuary throughout the human history, Sardinia could 
represent an ideal place to detect immunogenic factors 
potentially involved in resistance or susceptibility to 
SARS-CoV-2 infection. Overall, the analysis of the HLA 
alleles and haplotype frequencies showed 7 HLA alleles 
or haplotypes with a protective effect against SARS-
CoV-2 infection, and 5 alleles or haplotypes that were 
associated with an increased susceptibility to infection. 
The most interesting alleles, after correction for multiple 
comparisons, were HLA-A*23:01 and HLA-DRB1*08:01. 
These two alleles were exclusively present in patients 
with a moderate or severe disease course. However, 
HLA-A*23:01 is an uncommon allele in the Sardinian 
population, and it is therefore difficult to assess its effect 
on the evolution of the disease. Only the HLA-A*30:02, 
B*14:02, C*08:02 three-loci haplotype maintained sta-
tistically significance relation after correction of the 
P values. This haplotype strongly correlated with dis-
ease severity [100]. Again in Italy, another study identi-
fied a significant association with a higher susceptibility 
to the disease was found for HLA-DRB1*15:01, HLA-
DQB1*06:02 and HLA-B*27:07 after applying the Bonfer-
roni’s correction for multiple tests [101]. The increased 
frequencies observed for DRB1*15:01 and DQB1*06:02 
in the 99 severe affected COVID-19 Italian patients 
were not in line with the results obtained in a larger sur-
vey [102], which did not show any association between 
HLA and COVID-19, but confirmed published data [103] 
identifying these two alleles among seven HLA suscepti-
bility alleles. Another interesting Italian study, through a 
geographic epidemiological analysis, observed that there 
are significant regional differences in the frequency of the 
two most common HLA haplotypes in the Italian popula-
tion between the northern, central and southern regions, 
with HLA-A*01:01 g-B*08:01 g-C*07:01 g-DRB1*03:01 g 
(the most frequent haplotype nationwide) show-
ing a decreasing frequency gradient, and HLA-
A*02:01  g-B*18:01  g-C*07:01  g-DRB1*11:04  g (the 
second most frequent haplotype) an increasing frequency 
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gradient from North to South. The geographical distribu-
tion of these haplotypes overlaps with that of COVID-
19 in Italy, being linearly and significantly correlated in 
a positive/direct way (suggestive of susceptibility) for the 
haplotype 1 and in a negative/inverse way (suggestive of 
protection) for the haplotype 2, both for incidence and 
mortality [104]. In Spain, a study conducted in the ICUs 
of 6 hospitals in the Canary Islands found a trend to a 
higher infection rate of the alleles HLA-A*32, HLA-B*39 
and HLA-C*16, but these p values were not significant 
after correction for multiple comparisons. Conversely, 
logistic regression analysis showed that the presence of 
the alleles HLA-A*11, HLA-C*01, HLA-DQB1*04 were 
associated with higher mortality after controlling for 
SOFA or APACHE-II [105]. A preprint article that con-
siders the increased risk of hospitalization as param-
eter suggests that HLA-A*11:01, HLA-DQA1*01:02 and 
HLA-C*04:01 alleles are associated with greater severity 
disease. This is especially evident for COVID-19 patients 
with HLA-C*04:01, in whom disease prognosis meas-
ured by mechanical ventilation-free days was statisti-
cally significant after Bonferroni’s correction and may 
hold potential clinical value [106]. Regarding the differ-
ent allele frequencies examined in that study, it must be 
emphasized that they vary greatly between regions, so 
it is well possible that alleles identified as risk alleles in 
some association studies have no weight in other popula-
tions, given their low presence in such populace [107].
Conclusions
The association between HLA and COVID-19 deserves 
investigations on larger patient cohorts. Only limited sets 
of HLA alleles have been studied. Another limitation of 
the studies could be that, at present, it is not possible to 
assess the relative importance of the HLA type in cor-
relation to known disease-modifying risk factors such 
as age and clinical comorbidities [108–111]. Meanwhile, 
these findings may provide new insights on pathogenesis 
of SARS-CoV-2, the design of vaccination programs, and 
more effective infection control to optimize the treat-
ment, to management of patients with the disease, to 
identify those at greatest risk, and to reduce morbidity 
and mortality. Identification of high-risk subjects sus-
ceptible to SARS-CoV-2 infection could help to prevent 
virus spreading, reducing public health burden and pri-
oritizing preventive medicine. Current scientific evidence 
suggests to integrate HLA testing into clinical trials and 
combine HLA typing with COVID-19 testing to more 
rapidly identify a predictor of viral severity in the popula-
tion, and potentially adapt vaccination strategies to geno-
typically at risk populations.
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